Attorneys for the plaintiffs did not return demands comment. Related StoriesNew initiative released to accelerate search for effective HIV vaccineGenvoya accepted as complete regimen for HIV treatmentNew computer model predicts degrees of HIV care engagementAbbott can be facing six additional antitrust lawsuits filed by 16 companies, the AP/Herald Tribune reports. Two various other lawsuits filed in Illinois have been dismissed . ‘The purchase price adjustment of Norvir was a legitimate response to advances that Abbott scientists made in treating HIV and captured the fair value of its new use as a bolster’ in mixture therapies,’ Abbott spokesperson Scott Stoffel said.Most individuals acquired an ECOG performance-status score of 1 1, had stage IV cancer, and were current or previous smokers . The baseline characteristics were balanced between the treatment groups, with small between-group imbalances in the %ages of male individuals and patients more youthful than 65 years of age. A median of 6 doses of nivolumab and 4 dosages of docetaxel were administered. Among the sufferers in the nivolumab group, 83 percent received at least 90 percent of the planned dose intensity. Among the patients in the docetaxel group, 66 percent received at least 90 percent of the prepared dose intensity.